Management of Diabetic Retinopathy in the Anti-Vascular Endothelial Growth Factor Era

Affiliations

¹ Philadelphia Retina Associates, Philadelphia, Pennsylvania.
² Gundersen Eye Institute, La Crosse, Wisconsin.
³ Department of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania.

Editorial

Robert M Carroll et al. Retina. 2021.

. 2021 Mar 1;41(3):461-463.

doi: 10.1097/IAE.0000000000003071.

¹ Philadelphia Retina Associates, Philadelphia, Pennsylvania.
² Gundersen Eye Institute, La Crosse, Wisconsin.
³ Department of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania.

No abstract available

References

1. The Diabetic Retinopathy Study Research Group. Diabetic retinopathy study. Report number 6. Design, methods, and baseline results. Report number 7. A modification of the Airlie House classification of diabetic retinopathy. Invest Ophthalmol Vis Sci 1981;21:147–226.
1. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs—an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology 1991;98:786–806.
1. Ip MS, Domalpally A, Hopkins JJ, et al. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol 2012;130:1145–1152.
1. Bressler SB, Liu D, Glassman AR, et al. Change in diabetic retinopathy through 2 years: secondary analysis of a randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab. JAMA Ophthalmol 2017;135:558–568.
1. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8. Ophthalmology 1981;88:583–600.